2016—The First Biotech Company to Focus on Senescence Launches 

Senescence has emerged as one of the primary drivers of aging identified so far. In 2016 the Buck supported the launch of Unity Biotechnology, the first company to focus on translating the science of senescence to medicines designed to increase healthspan. The company, focused in large part on Buck science, was first located on our campus.

Leave a Comment